Phase 4 N=43 Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers
Visual Acuity
Primary: Visual Acuity (logMAR) — 0.15; 0.21; 0.02; 0.05 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=318 A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.44; -1.23; -1.31; -1.40 Percentage of glycosylated hemoglobin — p=<.001
N/A N=162 Invasive Candidiasis in Saudi ICUs
Invasive Candidiasis
Primary: Hospital Mortality — 95 Participants
Phase 3 N=5,449 Complementary Food Supplements for Reducing Childhood Undernutrition
Stunting · Wasting
Primary: Stunting in Children at 18 mo — 559; 542; 341; 300 Participants
N/A N=33 Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Feasibility of At Home tDCS Intervention — 25 Participants
Phase 3 N=466 Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
Bipolar I Disorder
Primary: Time From Randomization to Recurrence of Any Mood Episode During Double-bind Placebo-controlled Phase. — NA; 308 Days — p=< 0.0001
Phase 2 N=23 A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
Chronic Renal Failure
Primary: Change From Baseline in Daily Urine Volume — 481.0 ml
Phase 3 N=29 Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients
Cocaine Dependence
Primary: Number of Participants With Relapse by Days 10 and 28 — 3; 8; 6; 3 Participants
N/A N=1,205 Educational Intervention to Improve HPV Vaccination Decision Quality
HPV Vaccination Decision Quality
Primary: Percent of Participants - Who Agreed They Felt Sure About the Best Choice Regarding the HPV Vaccine at Post-intervention — 94; 95; 89 Percent of participants — p=0.069
Phase 1 N=24 A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 0; 0; 0 Participants
Phase 2 N=505 A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks — -6.1876; -5.2065; -6.0430; -5.5430 percent predicted FVC/year — p=0.4555
Phase 2 N=200 A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
Anemia
Primary: Percentage of Participants With Response to Treatment Based on Hemoglobin Levels — 46.2 percentage of participants
Phase 2 N=20 A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
Epilepsy
Primary: Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33 — 330; 440; 329; 461 ng/mL
Phase 2 N=183 PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
Chronic Kidney Disease Requiring Hemodialysis
Primary: Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment. — -1.84; -2.59; -3.17; -3.78 mg/dL
Phase 3 N=609 A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the Microbiological Modified ITT (mMITT) Population at Day 5 — 88; 91.4; 10.5…